Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Observationeel langetermijnonderzoek naar de effectiviteit en veiligheid van Lecigon bij patiënten met de ziekte van Parkinson in een gevorderd stadium (ELEGANCE)

1 oktober 2026 bijgewerkt door: Britannia Pharmaceuticals Ltd.

ELEGANCE - Een niet-interventioneel onderzoek naar de langetermijneffectiviteit en veiligheid van Levodopa-Entacapone-Carbidopa Intestinal Gel (Lecigon®) bij patiënten met gevorderde ziekte van Parkinson in routinezorg

This observational study is designed to collect data on the use of the drug Lecigon® in daily clinical practice. The study is organised and funded by a pharmaceutical company called Britannia Pharmaceuticals Ltd (Britannia).

Lecigon® is prescribed by physicians in advanced Parkinson's disease when patients suffer from uncontrollable fluctuations in mobility, so-called motor fluctuations, which cannot be adjusted well with oral treatment, i.e. medication for swallowing.

In this study, data on the effect and possible side effects from everyday treatment with Lecigon® will be collected and scientifically evaluated. The study is intended to supplement the results of previous clinical studies with clinical data in routine medical care, collected from approximately 300 patients.

Studie Overzicht

Gedetailleerde beschrijving

Study design:

Non-interventional study, primary data collection.

No visits or measurements will be made mandatory by the observational plan. The assignment of patients to Lecigon® not decided in advance by the study's observational plan but falls within current practice. Prescription of Lecigon® occurred before and independently of the decision to include the patient in the study.

The participating centres will offer participation in the ELEGANCE study to all patients who receive treatment with Lecigon® part of routine clinical practice. From patients, who switched to treatment with Lecigon® prior to signing of informed consent, baseline data will be collected retrospectively.

The planned non-interventional study aims to collect real-world data on the effectiveness and safety of Lecigon® as a therapy for advanced Parkinson´s Disease in routine care in Germany and Austria. The study will be expanded to additional European countries as soon as marketing authorisation in these countries and commercial stock will be available.

Primary Objectives:

  • Long-term effectiveness of Lecigon®
  • Long-term safety of Lecigon®

Secondary Objectives:

  • Patient non-motor symptoms and quality of life
  • Healthcare resource utilisation by patients

Studietype

Observationeel

Inschrijving (Werkelijk)

312

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studie Locaties

      • Bruges, België, 8000
        • AZ Sint-Jan
      • Edegem, België, 2650
        • Antwerp University Hospital
      • Ghent, België
        • Ghent University Hospital
      • Liège, België
        • University Hospital Liege
      • Tournai, België, 7500
        • Centre Hospitalier de Wallonie picarde (Chwapi)
      • Sofia, Bulgarije, 1113
        • Sveti Naum
      • Copenhagen, Denemarken, 2400
        • Bispebjerg Hospital
      • Bad Segeberg, Duitsland, 23795
        • Segeberger Kliniken GmbH Neurologisches Zentrum
      • Beelitz-Heilstätten, Duitsland, 14547
        • Kliniken Beelitz GmbH Neurologisches Fachkrankenhaus für Bewegungsstörungen/Parkinson
      • Berlin, Duitsland, 10117
        • Charité - Universitätsmedizin Berlin
      • Cologne, Duitsland
        • Uniklinik Köln
      • Coppenbrügge, Duitsland, 31863
        • Krankenhaus Lindenbrunn
      • Essen, Duitsland, 45147
        • Klinik für Neurologie - Universitätsklinikum Essen
      • Freiburg im Breisgau, Duitsland, 79106
        • Universitätsklinikum Freiburg, Klinik für Neurologie und Neurophysiologie
      • Göttingen, Duitsland, 37075
        • Zentrum für Seltene Erkrankungen Göttingen
      • Marburg, Duitsland, 35043
        • Universitätsklinikum Giessen und Marburg
      • Oldenburg, Duitsland, 26122
        • Evangelisches Krankenhaus Oldenburg
      • Osnabrück, Duitsland, 49076
        • Klinikum Osnabrück GmbH Klinik für Neurologie
      • Tübingen, Duitsland, 72076
        • Universitätsklinikum Tübingen
      • Ulm, Duitsland, 89081
        • RKU - Universitäts und Rehabilitationskliniken Ulm gGmbH
      • Wolfach, Duitsland, 77709
        • Parkinson-Klinik Ortenau
      • Budapest, Hongarije
        • Semmelweis Egyetem Neurológiai Klinika Budapest
      • Pécs, Hongarije, 7623
        • Pécsi Tudományegyetem Klinikai Központ Szemészeti Klinika
      • Szeged, Hongarije, 6725
        • SZTE Szent-Györgyi Albert Klinikai Közpon
      • Dublin, Ierland, D07 R2WY
        • The Dublin Neurological Institute, Mater Hospital
      • Dublin, Ierland, D04 T6F4
        • St. Vincent's University Hospital
      • Osijek, Kroatië, 31000
        • UHC Osijek, J. Klinici za neurologiju
      • Rijeka, Kroatië
        • University Hospital Centre Rijeka (KBC Rijeka)
      • Zagreb, Kroatië, 10000
        • University Hospital Centre (KBC Zagreb)
      • Zagreb, Kroatië, 10000
        • Klinička bolnica Dubrava
      • Groningen, Nederland, 97139713
        • University Medical Center Groningen
      • Graz, Oostenrijk, 8036
        • Universitätsklinik für Neurologie, Medizinische Universität Graz
      • Hermagor, Oostenrijk, 9620
        • Abteilung für Neurologische Rehabilitation, Gailtal-Klinik
      • Innsbruck, Oostenrijk, 6020
        • Universitätsklinik für Neurologie, Medizinische Universität Innsbruck
      • Linz, Oostenrijk, 4020
        • Kepler Universitätsklinikum
      • Brasov, Roemenië, 500326
        • Emergency Hospital Brasov, Spitalul Clinic Județean de Urgență Brașov
      • Bucharest, Roemenië, 050098
        • Bucharest University Emergency Hospital
      • Bucharest, Roemenië
        • Fundeni Clinical Institute
      • Bucharest, Roemenië, 011461
        • Spitalul Universitar de Urgență Elias
      • Bucharest, Roemenië, 020125
        • Colentina Hospital Bucharest
      • Cluj-Napoca, Roemenië, 400347
        • County Emergency Hospital Cluj-Napoca
      • Constanța, Roemenië, 900591
        • County Clinical Emergency Hospital of Constanta
      • Timișoara, Roemenië, 300723
        • Timiş County Emergency Clinical Hospital- Neurology 1
      • Timișoara, Roemenië, 300723
        • Timiş County Emergency Clinical Hospital
      • Târgu Mureş, Roemenië, 540136
        • Emergency County Hospital Targu Mures
      • Ljubljana, Slovenië, 1000
        • Department of Neurology, University Medical Centre
      • Maribor, Slovenië, 2000
        • Univerzitetni klinični center Maribor
      • Barcelona, Spanje, 08025
        • Hospital de la Santa Creu i Sant Pau
      • Madrid, Spanje, 28040
        • Hospital Clínico San Carlos
      • Madrid, Spanje, 28034
        • Hospital Universitario Ramón y Cajal
      • Madrid, Spanje
        • Hospital de la Princesa
      • Seville, Spanje, 41013
        • Hospital Virgen del Rocio
      • Brno, Tsjechië
        • Masaryk university
      • Olomouc, Tsjechië
        • Fakultní nemocnice Olomouc
      • Gothenburg, Zweden, 413 45
        • Sahlgrenska University Hospital
      • Lund, Zweden
        • Skånes universitetssjukhus Lund
      • Uppsala, Zweden, 751 85
        • Uppsala university hospital

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

18 jaar en ouder (Volwassen, Oudere volwassene)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Allemaal

Bemonsteringsmethode

Niet-waarschijnlijkheidssteekproef

Studie Bevolking

Treating physician's normal patient pool

Beschrijving

Inclusion Criteria:

  • Adult Patients (18 years old and over) with Advanced Parkinson Disease already under treatment with Lecigon® (for up to 3 months before giving informed consent) in accordance with the Summary of Product Characteristics (SmPC)
  • Patients or legal representative must have signed informed consent to participate in the study
  • Patients are not taking part in another clinical (interventional) study at the same time

Exclusion Criteria:

  • Patients with contraindications as defined in the current version of the SmPC for Lecigon®
  • Patients who will not be seen again for their follow up care at the investigator's site after commencement of Lecigon® therapy
  • Patients with pump placement or pump use issues, e.g. patients with acute severe illness, patients unable to perform pump therapy, and in case of lacking compliance due to severe dementia, agitation or alcohol abuse

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Observatiemodellen: COHORT
  • Tijdsperspectieven: OTHER

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Change in OFF time from baseline up to 24 months, or treatment or study discontinuation
Tijdsspanne: 24 months

To assess the effectiveness of Lecigon® treatment on the change in OFF time (h/day) from baseline up to 24 months, or treatment or study discontinuation as measured by Movement Disorder Society-Unified Parkinson's Disease Rating Scale IV Scores (MDS-UPDRS IV- motor complications)

24 months
Change in activities of daily living from baseline up to 24 months, or treatment or study discontinuation
Tijdsspanne: 24 months

To assess the effectiveness of Lecigon® treatment on the change in motor experiences of daily living from baseline up to 24 months, or treatment or study discontinuation as measured by Movement Disorder Society-Unified Parkinson's Disease Rating Scale II Scores (MDS-UPDRS II - motor experiences of daily living)

24 months
Change in Daily Levodopa dose from baseline up to 24 months, or treatment or study discontinuation
Tijdsspanne: 24 months

To assess the effectiveness of Lecigon® treatment on the change in Daily Levodopa dose [mg/day] from baseline up to 24 months, or treatment or study discontinuation as measured by morning bolus, continuous flow, extra boli, oral doses

24 months
Usage of other Anti-Parkinsonian medicinal products from baseline up to 24 months, or treatment or study discontinuation
Tijdsspanne: 24 months

To assess the effectiveness of Lecigon® treatment as measured by usage of other anti-Parkinsonian medicinal products (e.g. levodopa, dopamine agonists, Monoamine Oxidase (MAO)-B inhibitors, amantadine from baseline up to 24 months, or treatment or study discontinuation

24 months
Usage of the Lecigon® pump from baseline up to 24 months, or treatment or study discontinuation
Tijdsspanne: 24 months

To assess the effectiveness of Lecigon® treatment use of programmed pump rate (2 or 3 rates) from baseline up to 24 months, or treatment or study discontinuation will be collected

24 months
Change in Clinical Global Impression of Improvement (CGI-I) from baseline up to 24 months, or treatment or study discontinuation
Tijdsspanne: 24 months

To assess the effectiveness of Lecigon® treatment on the change in Clinical Global Impression of Improvement (CGI-I) from baseline up to 24 months, or treatment or study discontinuation as measured by Clinical Global Impression of Improvement Scale Score (CGI-I)

24 months
Change in Patient Global Impression of Change from baseline up to 24 months, or treatment or study discontinuation
Tijdsspanne: 24 months

To assess the effectiveness of Lecigon® treatment on the change in Patient Global Impression of Change (PGI-C) from baseline up to 24 months, or treatment or study discontinuation as measured by Patient Global Impression of Change Scale Score (PGI-C)

24 months
Satisfaction with treatment from baseline up to 24 months or treatment or study discontinuation
Tijdsspanne: 24 months

To assess the effectiveness with Lecigon®, satisfaction with treatment will be assessed in terms of pump size, weight, noise, handling and overall pump satisfaction from baseline up to 24 months or treatment or study discontinuation as measured by device satisfaction scale score between 0 (absolutely unsatisfied) to 10 (absolutely satisfied) for each item.

24 months
Occurrence of AEs and SAEs from baseline up to 24 months or treatment or study discontinuation
Tijdsspanne: 24 months

To assess the long-term safety of Lecigon® treatment Adverse Events (AEs) and Serious Adverse Events (SAEs) (including drug-related, device- and procedure-related Adverse Drug Reactions (ADRs) and Serious Adverse Drug Reactions (SADRs), AEs of special interest) from time of Informed consent to study completion for up to 24 months or treatment or study discontinuation will be collected

24 months

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Change in Non-Motor Symptoms from baseline up to 24 months, or treatment or study discontinuation
Tijdsspanne: 24 months

To assess the impact of Lecigon® treatment on the change in Non-Motor Symptoms from baseline up to 24 months, or treatment or study discontinuation as measured by Non-Motor Symptom Scale Scores (NMSS)

24 months
Change in Sleep Quality from baseline up to 24 months, or treatment or study Discontinuation
Tijdsspanne: 24 months

To assess the impact of Lecigon® treatment on the change in sleep quality from baseline up to 24 months, or treatment or study discontinuation as measured by Parkinson's disease sleep Scale-2 Score (PDSS-2)

24 months
Change in Activities of daily living from baseline up to 24 months, or treatment or study discontinuation
Tijdsspanne: 24 months

To assess the impact of Lecigon® treatment on the change in activities of daily living from baseline up to 24 months, or treatment or study discontinuation as measured by Movement Disorder Society-Unified Parkinson's Disease Rating Scale Ib Score (MDS-UPDRS Ib - non-motor experiences of daily living)

24 months
Change in Quality of Life from baseline up to 24 months or treatment or study discontinuation
Tijdsspanne: 24 months

To assess the impact of Lecigon® treatment on the change in quality of life from baseline up to 24 months, or treatment or study discontinuation as measured by Parkinson's Disease Questionnaire total score (PDQ-8 or PDQ-39)

24 months
Usage of Healthcare resources from baseline up to 24 months, or treatment or study discontinuation
Tijdsspanne: 24 months

To assess the impact of Lecigon® treatment on usage of Healthcare resources as measured by additional hospitalisation due to complications out of scope of nurse support team since the last visit

24 months

Andere uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Change in Body weight from baseline up to 24 months, or treatment or study discontinuation
Tijdsspanne: 24 months

To assess the impact of Lecigon® treatment on vital signs as measured by change in the Body weight (Kg) from baseline up to 24 months, or treatment or study discontinuation

24 months
Change in Blood pressure from baseline up to 24 months, or treatment or study discontinuation
Tijdsspanne: 24 months

To assess the impact of Lecigon® treatment on vital signs as measured by change in the Blood pressure (mmHg) from baseline up to 24 months, or treatment or study discontinuation

24 months
Change in Pulse from baseline up to 24 months, or treatment or study discontinuation
Tijdsspanne: 24 months

To assess the impact of Lecigon® treatment on vital signs as measured by change in the Pulse (bpm) from baseline up to 24 months, or treatment or study discontinuation

24 months
Change in the Liver function tests from baseline up to 24 months, or treatment or study discontinuation
Tijdsspanne: 24 months

To assess the impact of Lecigon® treatment on laboratory results as measured by change in the Liver function tests from baseline up to 24 months or treatment or study discontinuation

24 months
Change in the full blood count from baseline up to 24 months, or treatment or study discontinuation
Tijdsspanne: 24 months

To assess the impact of Lecigon® treatment on laboratory results as measured by change in the full blood count including B12 metabolism panel from baseline up to 24 months or treatment or study discontinuation

24 months
Change in the ECG from baseline up to 24 months, or treatment or study discontinuation
Tijdsspanne: 24 months

To assess the impact of Lecigon® treatment on laboratory results as measured by change in the ECG from baseline up to 24 months or treatment or study discontinuation

24 months
Change in the Renal function tests from baseline up to 24 months, or treatment or study discontinuation
Tijdsspanne: 24 months

To assess the impact of Lecigon® treatment on laboratory results as measured by change in the Renal function tests from baseline up to 24 months or treatment or study discontinuation

24 months

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

6 juli 2021

Primaire voltooiing (Geschat)

7 oktober 2026

Studie voltooiing (Geschat)

7 oktober 2026

Studieregistratiedata

Eerst ingediend

29 juli 2021

Eerst ingediend dat voldeed aan de QC-criteria

3 september 2021

Eerst geplaatst (Werkelijk)

14 september 2021

Updates van studierecords

Laatste update geplaatst (Werkelijk)

6 oktober 2026

Laatste update ingediend die voldeed aan QC-criteria

1 oktober 2026

Laatst geverifieerd

1 oktober 2026

Meer informatie

Termen gerelateerd aan deze studie

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Nee

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren